Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302)
- Citation:
- J Clin Oncol vol 39 (no. 15_suppl) 6076
- Meeting Instance:
- ASCO 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4157
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Novartis/GSK
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Eric Sherman Nathan R. Foster Yungpo Bernard Su Ardaman Shergill Alan Ho Bhavana Konda Ronald A. Ghossein Ian Ganly Gary K. Schwartz
- Networks:
- COLUMBIA, CORA, LAPS-IL057, LAPS-MN026, LAPS-NY016, LAPS-OH007
- Study
- Alliance-A091302
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: